Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

Annovis Bio (NYSE: ANVS), a Phase 3 biotech company developing buntanetap for neurodegenerative diseases, received notice from the NYSE on October 29, 2026, that it no longer meets continued listing standards. The company's 30-day average market capitalization was approximately $48.4 million (below the $50 million threshold) and it reported a stockholders' deficit of $4.3 million as of June 30, 2026. Annovis has 45 days to submit a compliance plan and 9 months to regain compliance, during which its stock will trade with a '.BC' designation indicating below-criteria status. Failure to comply could result in NYSE delisting proceedings.